Abstract
In the nasal mucosa of patients with allergic rhinitis, CD4+T precursor cells have been demonstrated to predominantly differentiate into Th2 cells rather than into Th1 cells. Cytokine therapy has been generally accepted to redress the imbalance of differentiation of Th0 into a Th1 or Th2 environment. To date, there are no reports about cytokine therapy for human allergic rhinitis, although there are a number of reports about general cytokine therapy in murine models of allergic rhinitis. Topical cytokine therapy has not been extensively investigated, however, recently, intranasal administration of cytokine, vector and antisense-nucleotide has been reported. The nasal mucosa presents numerous advantages as a target tissue for drug delivery, such as a large mucosal area, rapid absorption, no pH or enzyme barrier, and no first-pass metabolism. The permeability of various particles through nasal mucosa is limited by the tight junctions present in abundance. Therefore, the feasibility and disadvantages of cytokine therapy are discussed in detail in this report.
| Original language | English |
|---|---|
| Pages (from-to) | 43-47 |
| Number of pages | 5 |
| Journal | Oto-Rhino-Laryngology Tokyo |
| Volume | 51 |
| Issue number | SUPPL. 1 |
| Publication status | Published - Aug 1 2008 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Otorhinolaryngology
Cite this
Cytokine therapy of allergic rhinitis. / Aoi, Noriaki; Kawauchi, Hideyuki; Yoshikai, Yasunobu.
In: Oto-Rhino-Laryngology Tokyo, Vol. 51, No. SUPPL. 1, 01.08.2008, p. 43-47.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Cytokine therapy of allergic rhinitis
AU - Aoi, Noriaki
AU - Kawauchi, Hideyuki
AU - Yoshikai, Yasunobu
PY - 2008/8/1
Y1 - 2008/8/1
N2 - In the nasal mucosa of patients with allergic rhinitis, CD4+T precursor cells have been demonstrated to predominantly differentiate into Th2 cells rather than into Th1 cells. Cytokine therapy has been generally accepted to redress the imbalance of differentiation of Th0 into a Th1 or Th2 environment. To date, there are no reports about cytokine therapy for human allergic rhinitis, although there are a number of reports about general cytokine therapy in murine models of allergic rhinitis. Topical cytokine therapy has not been extensively investigated, however, recently, intranasal administration of cytokine, vector and antisense-nucleotide has been reported. The nasal mucosa presents numerous advantages as a target tissue for drug delivery, such as a large mucosal area, rapid absorption, no pH or enzyme barrier, and no first-pass metabolism. The permeability of various particles through nasal mucosa is limited by the tight junctions present in abundance. Therefore, the feasibility and disadvantages of cytokine therapy are discussed in detail in this report.
AB - In the nasal mucosa of patients with allergic rhinitis, CD4+T precursor cells have been demonstrated to predominantly differentiate into Th2 cells rather than into Th1 cells. Cytokine therapy has been generally accepted to redress the imbalance of differentiation of Th0 into a Th1 or Th2 environment. To date, there are no reports about cytokine therapy for human allergic rhinitis, although there are a number of reports about general cytokine therapy in murine models of allergic rhinitis. Topical cytokine therapy has not been extensively investigated, however, recently, intranasal administration of cytokine, vector and antisense-nucleotide has been reported. The nasal mucosa presents numerous advantages as a target tissue for drug delivery, such as a large mucosal area, rapid absorption, no pH or enzyme barrier, and no first-pass metabolism. The permeability of various particles through nasal mucosa is limited by the tight junctions present in abundance. Therefore, the feasibility and disadvantages of cytokine therapy are discussed in detail in this report.
UR - http://www.scopus.com/inward/record.url?scp=53749098036&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=53749098036&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:53749098036
VL - 51
SP - 43
EP - 47
JO - Oto-Rhino-Laryngology Tokyo
JF - Oto-Rhino-Laryngology Tokyo
SN - 0386-9687
IS - SUPPL. 1
ER -